We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Profacgen's Effector Function Assays for Antibody Therapeutics provide quantitative, reproducible evaluation of Fc-mediated immune mechanisms that define the therapeutic efficacy and safety profile of antibody-based biologics.
Antibody effector functions—mediated through interactions between the Fc region and immune effector cells or complement proteins—are critical determinants of clinical performance. The ability to measure ADCC, CDC, and ADCP with precision, consistency, and biological relevance directly supports decision-making across therapeutic antibody development, from candidate screening to IND-enabling characterization and biosimilar comparability assessment.
What Are Antibody Effector Functions?
Figure 1. Antibody-mediated effector functions ADCC, ADCP, and CDC are significantly affected by changes in IgG glycosylation. (Colomb et al., 2019)
Antibody effector functions are Fc-mediated immune mechanisms that enable therapeutic antibodies to eliminate target cells through engagement with innate immune components. These functions are essential for the therapeutic activity of many antibody classes and must be characterized with precision to support development decisions.
ADCC (Antibody-Dependent Cellular Cytotoxicity): NK cell-mediated killing of target cells, triggered by FcγRIIIa (CD16a) engagement on the surface of natural killer cells
CDC (Complement-Dependent Cytotoxicity): Complement-mediated target cell lysis, initiated by C1q binding to the antibody Fc region and subsequent activation of the classical complement cascade
ADCP (Antibody-Dependent Cellular Phagocytosis): Macrophage-mediated phagocytosis of target cells, driven by Fcγ receptor engagement on phagocytic cells
Reliable quantification of these mechanisms is a prerequisite for therapeutic antibody characterization, comparability assessment, and regulatory submission. When your program depends on functional validation rather than binding data alone, effector function assays become a strategic enabler.
Our Effector Function Assay Portfolio
Our capabilities are organized into three interconnected assay platforms, each addressing a critical Fc-mediated mechanism. These modules can be deployed independently or integrated into a comprehensive effector function characterization workflow.
Measurement of macrophage-mediated target cell engulfment
Primary macrophage and monocyte-derived cell models
Multiple Fcγ receptor engagement assessment
Flow cytometry and imaging-based phagocytosis quantification
Support for antibody opsonization and clearance evaluation
Assay Platforms
Profacgen employs multiple assay platforms to accommodate diverse antibody formats, target cell types, and functional readout requirements. Platform selection is guided by desired sensitivity, throughput, mechanistic resolution, and regulatory context.
Cell-Based Assays
Direct measurement of effector function using physiologically relevant cell systems, including primary immune cells, engineered cell lines, and target-expressing cell models.
Reporter Gene Assays
High-throughput, quantitative assessment of Fc receptor signaling pathways using engineered reporter cell lines with luciferase or fluorescent readouts.
Flow Cytometry-Based Assays
Multiparametric analysis of cell killing, phagocytosis, and receptor expression using fluorescent labeling and high-content acquisition.
Imaging-Based Assays
Visual confirmation and quantitative analysis of effector-target interactions, phagocytosis events, and morphological changes using live-cell imaging.
Applications
Our Effector Function Assays support a broad spectrum of applications across therapeutic antibody development and characterization:
Therapeutic Antibody Development: Quantitative assessment of effector function potency to support lead selection, optimization, and mechanism-of-action validation
Bispecific Antibodies: Evaluation of dual-target engagement and Fc-mediated effector activity in complex antibody architectures
Fc Engineering: Characterization of Fc-modified variants designed to enhance, reduce, or eliminate specific effector functions
Biosimilar Assessment: Rigorous comparability testing to demonstrate functional equivalence between innovator and candidate products
Antibody Optimization: Iterative refinement of antibody candidates based on quantitative effector function data and structure-activity relationships
Why Choose Profacgen?
Multiple Effector Function Platforms: We provide a comprehensive suite of ADCC, CDC, and ADCP assays, enabling integrated characterization or focused evaluation of individual mechanisms.
Customized Assay Development: Our team develops and validates assay formats tailored to your specific antibody format, target biology, and regulatory requirements.
Qualified Cell Models: We maintain a diverse portfolio of effector and target cell models, including primary cells, engineered lines, and reporter systems, to match your mechanistic and sensitivity needs.
Robust Data Analysis: We emphasize statistical rigor, reproducibility, and structured reporting to support internal decision-making, regulatory submissions, and cross-program comparability.
Typical Engagement Workflow
Our engagement workflow is designed to align assay development and execution with your program timeline and decision points:
Consultation: Discussion of antibody characteristics, target biology, and intended application to define assay strategy
Assay Design: Selection of appropriate cell models, readout platforms, and experimental parameters based on program requirements
Testing: Execution of assays under controlled conditions with predefined acceptance criteria and quality controls
Analysis: Statistical evaluation of effector function potency, consistency, and comparability across samples
Report: Structured documentation of methods, results, and interpretation for internal review or regulatory submission
Whether you require evaluation of a single effector mechanism or a comprehensive Fc-mediated functional characterization, our Effector Function Assays for Antibody Therapeutics are designed to accelerate your path from candidate selection to clinical development.
Explore our core modules above or contact us to discuss a customized solution tailored to your specific antibody program.
References:
Colomb F, Giron LB, Trbojevic-Akmacic I, Lauc G, Abdel-Mohsen M. Breaking the glyco-code of hiv persistence and immunopathogenesis. Curr HIV/AIDS Rep. 2019;16(2):151-168. doi:10.1007/s11904-019-00433-w
Gogesch P, Dudek S, Van Zandbergen G, Waibler Z, Anzaghe M. The role of fc receptors on the effectiveness of therapeutic monoclonal antibodies. IJMS. 2021;22(16):8947. doi:10.3390/ijms22168947
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
Figure 1. Antibody-mediated effector functions ADCC, ADCP, and CDC are significantly affected by changes in IgG glycosylation. (Colomb et al., 2019)
